Subject: A survey to assess perception of triple fixed dose combination of empagliflozin, sitagliptin and metformin in the various patient profiles of type 2 diabetes (ADVANCE)
Type 2 diabetes mellitus (T2D) is an important cause of morbidity and mortality, with a growing prevalence worldwide. A consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) advises that the goals of treatment for patients with T2D are to prevent or delay the development of complications while maintaining quality of life. This involves the control of glycemia and cardiovascular (CV) risk factor management, and a patient-centered approach to care. The choice of pharmacologic agents should take account of comorbidities, in particular, the presence of atherosclerotic CV disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD), in addition to the risk of hypoglycemia, impact on weight, cost, potential for side effects, and patient preferences. Since T2D is a major risk factor for CV disease (CVD), which is the most common cause of death in patients with T2D, the impact of treatment on CV risk is an important consideration.
For patients who have ASCVD or indicators of high-risk, established kidney disease or heart failure, an SGLT2 inhibitor with demonstrated CV benefit is recommended, independent of baseline or HbA1c target. For patients requiring additional treatment for control of glycemia, similar consideration should guide the addition of a third agent, which may include a dipeptidyl peptidase-4 (DPP-4) inhibitor. The use of an SGLT2 inhibitor, DPP-4 inhibitor may also be added alone or in combination in patients without ASCVD, HF, or CKD if there is a need to minimize hypoglycaemia.
Adherence to the prescribed regimen is an important predictor of clinical outcomes and patient adherence is known to decline as the number of medications increases.7Since the management of T2D frequently requires combination therapy, the use of FDC therapy can reduce the pill burden leading to a simplified treatment regimen, reduce medication costs to patients, and improve adherence to therapy.
A new FDC of extended-release metformin (metformin XR) plus an SGLT2 inhibitor, empagliflozin, and a DPP-4 inhibitor, sitagliptin, has recently been approved for the treatment of T2D. These agents are attractive choices for patients needing glucose lowering with multiple agents, in line with recommended treatment options for treatment intensification for T2D
The purpose of this survey is to understand the current perception of triple fixed dose combination of empagliflozin, sitagliptin and metformin in the various patient profiles of type 2 diabetes and also help to address the current need gaps to look at potential interventions at patient level.
If you agree to participate, you will need to provide assessment response, on to the standard questionnaire form. A link will be provided for the same on your registered email address.
We trust you and we are partners in safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey.
If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})